Introduction
============

The first *qnr* gene was observed in the late 1990s and described as a plasmid-mediated quinolone resistance gene (PMQR). Since that, five types of *qnr* genes have been reported: *qnrA*, *qnrB*, *qnrC*, *qnrD*, and *qnrS*. Their sequences are deposited at the following website (<http://www.lahey.org/qnrStudies/>). Most were observed in *Enterobacteriaceae*, located on large conjugative multi-resistant plasmids, such as pMG252 seen in the original *qnrA1*-positive strain \[[@B1]\].

The *qnrD* gene was first described in 2009 on a 4270 bp plasmid present in a human clinical isolate of *Salmonella enterica* serovar *Kentucky* and three *Salmonella enterica* serovar *Bovismordificans* isolates from China \[[@B2]\]. Since this report, *qnrD* was found in *Escherichia coli*\[[@B3]\], *M. morganii*\[[@B4]\], *P. Mirabilis*\[[@B4]\],\[[@B5]\], *Pseudomonas aeruginosa*\[[@B5]\] and *Providencia rettgeri*\[[@B6]\].

We describe the new *gyrB* and *parC* mutations in a clinical isolate of *M. morganii* harbouring the rare *qnrD gene that is first reported in Tunisia*.

Material and methods
====================

Case presentation
-----------------

On 22 November 2012, a 76-years old male presented to the urology department with hematuria and burning micturition that were neglected by the patient since six months. On presentation, he was not febrile with normal vital signs and negative urine culture.

The ultrasonography shows a bladder of budding aspect, bifocal with long axis (3 cm). The histopathology revealed urothelial carcinoma infiltrating high-grade bladder (II pTa). On 30/11/2012, underwent a transurethral resection of bladder tumor. A double-current probe 18 c was also introduced.

On 19/01/2013 the patient presented an acute pyelonephritis and the urine culture showed the presence of quinolone resistant *M. morganii.* The empiric antibiotic therapy consisted of three doses a day of 2_g Ampicillin during 4 days. Urine culture subsequently yielded *M.morganii*. The antibiotic regime was then replaced with three doses a day of cefoxitin 1_g during one week. After this, the urine culture was negative but the haematuria still existed.

Bacterial strain
----------------

*M. morganii* was isolated from urine and identified using the Vitek 2 identification system (bioMérieux, Marcy l'Etoile, France). The antimicrobial susceptibilities of the *M. morganii* isolate were determined on Mueller-Hinton agar by the standard disk diffusion procedure as described by the Antibiogram Committee of the French Society for Microbiology (<http://www.sfm.asso.fr>). The microbroth dilution technique was used to determine the minimal inhibitory concentrations (MIC) for norfloxacin, ofloxacin, ciprofloxacin and levofloxacin.

PMQR screening
--------------

The *qnrA, qnrB, qnrS, qnrC, qnrD, aac-Ib*, and *qepA* genes were detected by PCR with the primer sets as described previously \[[@B2]\],\[[@B7]\]-\[[@B10]\].

*QnrD* primers were used also for the clinical survey of *qnrD* gene in other quinolone resistance *Enterobacteriacae* (n = 95) collected from October 2010 to June 2013: *Klebsiella pneumoniae* (n = 59), *Enterobacter cloaceae* (n = 17), *Citrobacter freundii* (n = 9), *Salmonella spp* (n = 6), *Providencia rettgerii* (n = 3), *M. morganii* (n = 1).

Conjugation
-----------

The transferability of *qnrD* gene between the *M. morganii* isolate and the *E. coli* J53Az^r^ recipient were carried out in LB broth. Cultures of donor and recipient cells in logarithmic phase (0.5 ml of each) were added to 4 ml of fresh LB broth and incubated overnight without shaking. Transconjugants were selected on Trypticase soy agar (TSA) plates containing sodium azide (100 μg/ml; Sigma Chemical Co., St. Louis, Mo.) for counterselection and gentamicin (10 μg/ml) to select for plasmid-encoded resistance.

Detection of mutations in the topoisomerase II and IV genes
-----------------------------------------------------------

The quinolone resistance-determinant regions (QRDRs) of *gyrA*, *gyrB*, *ParC* and *parE* was amplified as described previously \[[@B11]\]. Products resulting from amplifications were subjected to sequencing. Analysis and comparison of nucleotide and amino acid sequence data were carried out using Lasergene software (version 7.1; DNASTAR, Wisconsin, USA), and programs available from the national Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov>).

Results
=======

Antibiotic susceptibility of M. morganii
----------------------------------------

The clinical strain of *M. morganii* showed a low level of resistance to beta-lactams due to its resistance to ampicillin, amoxicillin, ticarcillin and piperacillin only. It was susceptible to amoxicillin/clavulanic acid, ticarcillin/clavulanic acid, piperacillin/tazobactam, cafalotin, cefamandol, cefoxitin, cefotaxim, ceftazidim, cefpirom, aztreonam, imipenem and ertapenem. This strain was resistant to gentamicin and tobramycin but susceptible to amikacin. It showed also, decreased susceptibility to trimethoprime/sulfamides and rifampicin. The MIC with microbroth dilution technique was 512 μg/ml for norfloxacin, 256 μg/ml for ofloxacin and ciprofloxacin and 64 μg/ml for levofloxacin.

Detection of PMQR genes
-----------------------

The PMQR screening with PCR revealed the presence of *qnrD* in *M.morganii* only. None of the other studied Enterobacteria harboured the *qnrD* gene. The sequencing result showed the presence of *qnrD1* in the *M. morganii* isolate. *qnrA, qnrB, qnrS, qnrC, aac-Ib-cr* and *qepA* genes were not found in this strain.

Conjugation
-----------

The conjugative reaction fails and the *qnrD* gene couldn't be transferred to *E.coli* J53.

Topoisomerase mutations
-----------------------

Sequencing of PCR products of QRDRs in *gyrB* and *parC* showed two mutations in the QRDR of *gyr B* at 463 and 464 codons. The first one is an S463A substitution and the second is an S464Y substitution.

Mutation was found also in the QRDR of *parC* at codon 80. It was an S80I substitution.

Discussion
==========

The Gram-negative *M. morganii* is found in the environment and as a part of the normal flora of humans. It has been considered as a rare cause of human infections. However, it is an important opportunistic pathogen in urinary tract, soft tissue infections and also in infections following surgery \[[@B12]\],\[[@B13]\]. In this case of study, the old age of the patient, the bladder tumor and its resection and the probe introduction after the surgery are risk factors leading to the urinary tract infection with the opportunistic *M. morganii*.

This *M. morganii* strain was highly resistant to quinolones and *qnrD* was detected. *qnrD* was not found to be self transmissible and it could have spread either on a mobilizable plasmid or on a transferable structure integrated into a conjugative plasmid \[[@B6]\]. The transfer of quinolone resistance due to *qnrD* is always studied on transformants never on transconjugants. In the study of Hu et al., *Proteus mirabilis* harbouring *qnrD* failed to transfer quinolone resistance to *E.coli* 600 by conjugation \[[@B14]\]. The MIC of ciprofloxacin in *E.coli* DH10B cells increased in the transformants carring the plasmid pBR322 with the cloned *qnrD* from 0,002 μg/ml to 0,06 μg/ml (by a factor 32) \[[@B2]\].

However, *qnrD* positive clinical strains described so far exhibited a high level of quinolone resistance with ciprofloxacin MIC ranging from 1 to higher then 32 μg/ml and they are likely to harbour other quinolone resistance mechanisms \[[@B14]\],\[[@B15]\]. Topoisomerase mutations have not been always investigated in *qnr*D positive clinical strains in order to evaluate how both mechanisms interact. The *gyrA* and *parE* primers used to amlify the QRDRs for Enterobacteria were not available for *M. morganii*. The study of Mazzariol A et *al.* couldn't to amplify *gyrA* and *parC* genes in this bacteria and this is due to its unknown genome \[[@B15]\].

To date, none of *M. morganii* was described with *gyrB* mutations. In this report, we described for the first time, two new *gyrB* mutations in *M. morganii*. In gram-negative bacilli, *gyrB* mutations are rare in clinical strains and they have been described at positions 426, 431, 447, 463, 464 and 466. The Ser 463Ala mutation has been linked to *Klebsiella oxytoca*\[[@B11]\].

This is the first report of the previous mutation in *qnrD* harbouring *M. morganii*. The Ser 464 Phe mutation has been linked to quinolone resistant *S.enterica*, *P.aeruginosa* and *P.mirabilis*\[[@B16]\]-\[[@B18]\]. In this study, the *gyrB* Tyr464 mutation was different from those described previously.

For *M. morganii,* the first *ParC* mutation was reported in the Tunisian study of Mahrouki et *al.*\[[@B19]\]. It was an S80I mutation associated to the *qnrS* 1 gene.

Another *ParC* mutation (S80R) was also described previously in this *Proteeae*\[[@B20]\]. In this study, we described the first S80I mutation in qnrD-positive *M. morganii*. This type of mutation was already observed in other Enterobacteria but never associated to the *qnrD* gene \[[@B21]\].

In summary, we have reported for the first time in Tunisia the rare *qnr*D in *M. morganii* and also found two new *gyrB* mutations (S463A and S464Y) and one *parC* substitution (S80I). In addition to *qnrD* gene, both mutations in *gyrB* and *ParC* could contribute to the high level of resistance to quinolones in this strain. The nosocomial infection caused by this bacterium invites further study of its epidemiologic evolution.
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